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1. INTRODUCTION {#mgg31304-sec-0005}
===============

Congenital disorders of glycosylation (CDG) type I is a group of rare recessive diseases caused by defects in up to 25 different genes involved in the pathway of protein N‐glycosylation (Péanne et al., [2018](#mgg31304-bib-0012){ref-type="ref"}). Actually, many proteins became hypoglycosylated. The identification of hypoglycosylated forms of transferrin is the gold standard of CDG diagnosis, which is completed by a genetic analysis. The relevance of N‐glycosylation for the folding, intracellular trafficking, and function of many proteins, particularly during development, support multiple mostly severe clinical phenotypes usually comprising also neurological involvement. However, there are patients with very mild phenotypes leading to underdiagnosis of CDG (Péanne et al., [2018](#mgg31304-bib-0012){ref-type="ref"}). However, there is a considerable clinical heterogeneity, both in terms of severity and organs affected (Péanne et al., [2018](#mgg31304-bib-0012){ref-type="ref"}). Thus, CDG might be underestimated (Péanne et al., [2018](#mgg31304-bib-0012){ref-type="ref"}).

2. MATERIAL AND METHODS {#mgg31304-sec-0006}
=======================

2.1. Ethical compliance {#mgg31304-sec-0007}
-----------------------

The study was performed in accordance with the International Guideline for Ethical Review of Epidemiological Studies and principles of the Declaration of Helsinki and approved by the ethics committee of Hospital Universitario Reina Sofía de Murcia (8/2013). A written informed consent from patients and healthy subjects was provided.

### 2.1.1. Patients {#mgg31304-sec-0008}

The study, in accordance to the ethical standards of the Declaration of Helsinki, was done in a consanguineous Spanish family (parents are cousins). Healthy subjects and PMM2‐CDG patients (Pascreau et al., [2019](#mgg31304-bib-0011){ref-type="ref"}) were also studied.

### 2.1.2. Biochemical and functional analysis {#mgg31304-sec-0009}

Antithrombin activity (anti‐F Xa) and antigen were determined by chromogenic methods and rocket immunoelectrophoresis, respectively. Western blot analysis was used to study plasma proteins (antithrombin, α1‐antitrypsin, F XI, F XII, and prothrombin). F XI was also studied by a clotting assay. Transferrin glycoforms were detected and quantified by HPLC and Q‐TOF (de la Morena‐Barrio et al., [2016](#mgg31304-bib-0003){ref-type="ref"}). An optimized reversed‐phase liquid chromatography multiple‐reaction monitoring mass spectrometry (RP‐LC‐MRM‐MS) method was used to characterize the glycopeptides of plasma antithrombin (Ruhaak et al., [2018](#mgg31304-bib-0013){ref-type="ref"}).

### 2.1.3. Genetic analyses {#mgg31304-sec-0010}

*SERPINC1* (OMIM: 107300), the gene encoding antithrombin, was evaluated by sequencing and multiplex ligation‐dependent probe amplification, as described (de la Morena‐Barrio et al., [2012](#mgg31304-bib-0002){ref-type="ref"}). Whole exome sequencing (Ion Torrent) was evaluated using VarAFT 2.6 and Illumina Variant Studio 3.0.12. Sequence variants were checked in public databases (ExAC, gnomAD, 1000 Genomes Project and EVS).

Validation and genotyping of the *ALG12* (OMIM: **\*** 607144) c.77T\>A p.(Val26Asp) variant was done by Sanger sequencing and PCR‐allelic specific restriction assay (PCR‐ASRA) with PshaI.

3. RESULTS {#mgg31304-sec-0011}
==========

This 25‐year‐old woman has a university degree, works as a teacher, and dances as well (Figure [1a](#mgg31304-fig-0001){ref-type="fig"}, supplementary information).

![Clinical, biochemical, and genetic characterization of the ALG12‐CDG. (a) Morphological aspect; (b) X‐ray images showing the scoliosis of the before and after the intervention; (c) Family tree. The proband is pointed by an arrow. Anti‐F Xa activity of antithrombin (AT) and the presence of the *ALG12* c.77T\>A p.(Val26Asp) variation are shown; (d) Identification of normal (full arrows) and hypoglycosylated forms (dashed arrows) of different proteins (antithrombin; α1‐antitrypsin; Factor XI --FXI; Factor XII --FXII‐, Prothrombin --PT‐) in plasma of the patient, a healthy subject (control), and a PMM2‐CDG patient. The proteins were detected by Western blot after separation using different electrophoretic conditions (Native and denaturing --*SD*‐ under reducing (R) and not reducing --NR‐ conditions). (e) Levels of the complex type glycan and the hybrid‐type glycan at glycopeptide LGACNDTLQQLMEVFK of plasma antithrombin in the ALG12‐CDG patient and a healthy control determined by RP‐LC‐MRM‐MS and calculated relative to the antithrombin quantitative peptide FDTISEK](MGG3-8-e1304-g001){#mgg31304-fig-0001}

At 4 years of age, a perimembranous ventricular septal defect with misalignment of the interventricular septum and deviation to the left ventricular outflow tract was diagnosed and was successfully corrected. At 11years, she presented idiopathic scoliosis (Figure[1b](#mgg31304-fig-0001){ref-type="fig"}). The scoliosis severely progressed until reaching right thoracic scoliosis T5‐T11 angle of 40° and left thoracic T11‐T1 angle of 35° associated to an important lordosis of 9°. Despite all treatments including the use of different braces (Milwaukee, Cheneoau), she required surgery (posterior arthrodesis from T2 to L3). Moreover, she reported recurrent upper mild respiratory viral infections during infancy.

At 18 years, a thrombophilia screening required by her gynecologist revealed antithrombin type I deficiency (50%). This was at first considered to be spontaneous or an artifact because this is an autosomal dominant disorder and no relatives had antithrombin deficiency (Figure [1c](#mgg31304-fig-0001){ref-type="fig"}). However, no *SERPINC1* variants were detected, but an antithrombin form with faster electrophoretic mobility was observed by western blot (Figure [1d](#mgg31304-fig-0001){ref-type="fig"}). RP‐LC‐MRM‐MS analysis of plasma antithrombin showed that the antithrombin‐derived tryptic glycopeptides KANK and SLTFN, which contains two of the N‐glycosylation sites of antithrombin (N167 and N187, respectively) are under‐occupied (ratio related to the non‐glycosylated FDTIS peptide: 0.72 and 0.67, respectively) in the patient compared with healthy controls (*N* = 40, ratio = 1.02 ± 0.19 and 0.85 ± 0.10, respectively). Moreover, the levels of two specific glycopeptides of antithrombin N‐glycosylation site N128 (LGACNDTLQQLMEVFK), one highest abundant complex type glycan and one disease‐specific hybrid‐type glycan, were assessed using targeted mass spectrometry. Levels of the glycopeptides of antithrombin immunoprecipitated from the ALG12‐CDG patient as well as one healthy control were calculated relative to the antithrombin quantitative peptide FDTIS. This study revealed highly similar levels of the complex type glycan in both samples, but the hybrid type glycan was only observed in the ALG12‐CDG patient (Figure [1e](#mgg31304-fig-0001){ref-type="fig"}). F XI also showed smaller forms in plasma (Figure [1d](#mgg31304-fig-0001){ref-type="fig"}). The electrophoretic pattern of antithrombin and F XI was similar to that seen in PMM2‐CDG patients (Figure [1d](#mgg31304-fig-0001){ref-type="fig"}). However, the hypoglycosylation of α1‐antitrypsin, F XII, and prothrombin was mild or undetectable (Figure [1d](#mgg31304-fig-0001){ref-type="fig"}). Finally, HPLC and Q‐TOF analysis of transferrin glycoforms revealed a CDG type I: asialo‐transferrin: 2.2% (normal range: 0%--1.5%) and disialo‐transferrin 13.8% (normal range: 1%--3%); and a‐ and mono‐glycotransferrin with pathological ratios (a‐/di‐: 0.00779 and mono‐/di‐: 0.27404; CDG‐I ranges: 0.00066--0.45300 and 0.03620--1.06000, respectively). A deficiency of F XI was detected by functional methods (F XI:C = 59%) and Western‐blot (Figure [1d](#mgg31304-fig-0001){ref-type="fig"}). Importantly, antithrombin and F XI deficiency, and hypoglycosylated forms of transferrin did not change in more than 50 samples collected during 7 years. Other parameters evaluated in the patient, glucose, urea, creatinine, total proteins, albumin, bilirubin, triglycerides, immunoglobulins (IgG; IgA and IgM), cholesterol (HDL and LDL), transaminases, hematocrit, and renal function, all were normal. Only she consistently showed low iron (27 µg/dl), ferritin (7 ng/ml), and saturation index of transferrin (6.3%), with normal folate, transferring, B12 vitamin, and hemoglobin levels.

Whole exome sequencing identified no pathogenic variants in *SERPINC1* or *F11*, but 90 variants were detected in 40 genes involved in CDG. After selecting those implicated in CDG type I, and excluding those located in introns without any role in splicing according to Human Splicing Finder predictions, six potential candidate variants detected (Table [S1](#mgg31304-sup-0002){ref-type="supplementary-material"}). Only a homozygous missense variant in *ALG12* \[c.77T\>A; p.(Val26Asp)\], confirmed by Sanger sequencing and by PCR‐ASRA, fulfilled the requirements of a recessive and rare disease. This variant, with very low MAF (not described in EXAC and 0.000008 in TOPMED; rs1208963988), was classified as damaging, or possible damaging by six in silico predictors (Table [S1](#mgg31304-sup-0002){ref-type="supplementary-material"}) and is not reported in the *ALG12* mutation database (<http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ALG12>). Her parents and sister were heterozygous carriers and did not present hypoglycosylation nor antithrombin or F XI deficiency (Figure [1c](#mgg31304-fig-0001){ref-type="fig"}).

Finally, the search for variants in genes involved in the clinical signs of the patient revealed a known heterozygous *ALG6* variant (p.Ser304Phe) and three new heterozygous variants in *KMT2D. KMT2D* encodes a lysine methyltransferase 2D involved in the Kabuki syndrome, a multisystem autosomal dominant disorder associated to structural cardiopathy and skeletal malformations (Digilio, Marino, Toscano, Giannotti, & Dallapiccola, [2001](#mgg31304-bib-0005){ref-type="ref"}): ENST00000301067.7: c.10673A\>G ENSP00000301067.7: p.(Glu3558Gly). MAF: 0; Polyphen: 0.968; Grantham: 98; ENST00000301067.7: c.3773G\>A ENSP00000301067.7: p.(Arg1258Gln). MAF:0; Polyphen: 0.895; Grantham: 43; ENST00000301067.7: c.2527T\>C ENSP00000301067.7: p.(Ser843Pro). MAF: 0; Grantham: 74.

4. DISCUSSION {#mgg31304-sec-0012}
=============

CDG is a broad group of hereditary, mostly multisystem disorders, usually diagnosed in the infancy. Thus, nobody might suspect a CDG in our patient. Actually, she was treated by cardiologists and traumatologist without suspicion of an underlying disease. The identification of antithrombin deficiency without *SERPINC1* defects and hypoglycosylation was the first clue of a CDG. Further evidences of a CDG include validation of hypoglycosylation in different proteins (antithrombin, F XI, and transferrin) by different methodological approaches (western blot, HPLC, Q‐TOF, and RP‐LC‐MRM‐MS). Whole exome sequencing leads to the diagnosis of ALG12‐CDG (CDG‐Ig). The *ALG12* encodes Dol‐P‐Man: Man7GlcNAc2‐PP‐Dol‐ mannosyltransferase (or mannosyltransferase 8) that catalyzes the addition of the eighth mannose residue onto the growing lipid‐linked oligosaccharide in the ER. Recently, this enzyme has also been associated to the first steps of maturation of the *N*‐glycan once attached to the protein (Golgi). Thus *ALG12* defects generated under‐occupancy of protein glycosylation sites and potentially aberrant high‐mannose and hybrid‐type structures (Figure [S1](#mgg31304-sup-0001){ref-type="supplementary-material"}) (Sturiale et al., [2019](#mgg31304-bib-0014){ref-type="ref"}), which was supported by the RP‐LC‐MRM‐MS analysis of plasma antithrombin in our patient.

Twelve unrelated ALG12‐CDG patients had been reported, showing 14 unique pathogenic variants (Chantret et al., [2002](#mgg31304-bib-0001){ref-type="ref"}; Di Rocco et al., [2005](#mgg31304-bib-0004){ref-type="ref"}; Eklund et al., [2005](#mgg31304-bib-0006){ref-type="ref"}; Grubenmann et al., [2002](#mgg31304-bib-0007){ref-type="ref"}; Kranz et al., [2007](#mgg31304-bib-0009){ref-type="ref"}; Murali et al., [2014](#mgg31304-bib-0010){ref-type="ref"}; Sturiale et al., [2019](#mgg31304-bib-0014){ref-type="ref"}; Tahata, Gunderson, Lanpher, & Morava, [2019](#mgg31304-bib-0015){ref-type="ref"}; Thiel et al., [2002](#mgg31304-bib-0016){ref-type="ref"}; Zdebska et al., [2003](#mgg31304-bib-0017){ref-type="ref"}), the first one reported in 2002 (Chantret et al., [2002](#mgg31304-bib-0001){ref-type="ref"}). Most were diagnosed in infancy or early childhood, and two in adulthood (30 and 44 years). Their phenotypes mainly comprised intellectual disability, growth deficiency, facial dysmorphism with short philtrum and thin upper lips, seizures or stroke‐like episodes, IgG deficiency (usually associated with recurrent infections), and antithrombin deficiency. The mildest phenotype was seen in two adult brothers: only mild/moderate intellectual disability, behavior disturbance, decreased antithrombin and, in one, facial dysmorphism. The present patient also presents a very mild phenotype consisting of scoliosis, a ventricular septal defect, recurrent infections, and decreased antithrombin and F XI activities. There is thus an important heterogeneity in the degree of severity and the phenotypic spectrum of this CDG. This phenomenon is not exceptional in CDG. In PMM2‐CDG, the phenotypes range from neonatal mortality to a near‐normal adulthood (Grunewald, [2009](#mgg31304-bib-0008){ref-type="ref"}). Other genetic factors probably play a role. In this context, we wonder what the contribution, if any, may be of the coexisting *KMT2D* variants and of the *ALG6* variant. It should be noted that scoliosis, ventricular septal defect, and joint laxity (she is a dancer!) also belong to the Kabuki syndrome spectrum. In conclusion, the present patient shows the mildest ALG12‐CDG presentation reported up to now, although further experimental studies, which might be done by specialized laboratories in ALG12, are required to demonstrate the pathogenic effects of this genetic variant and the associated mechanism.
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